Literature DB >> 2443538

Characteristics of prostate-derived growth factors for cells of the osteoblast phenotype.

M Koutsilieris1, S A Rabbani, H P Bennett, D Goltzman.   

Abstract

We examined the characteristics of mitogens extracted from human benign prostatic hyperplasia and prostatic adenocarcinoma tissue. Although mitogens for fetal rat skin fibroblasts as well as for rat calvarial osteoblasts and osterosarcoma cells were found, distinct entities that acted selectively in cells of the osteoblast phenotype could be obtained by sequential reverse-phase high performance liquid chromatography. Two peptides with apparent molecular weights of 10,000 and 13,000 D were derived from hyperplastic tissue, whereas a single moiety of 10,000 D was obtained from malignant tissue. These entities increased cell numbers and alkaline phosphatase activity in osteoblastlike cells consistent with effects on both growth and differentiation. Prostatic peptides did not stimulate adenylate cyclase in osteosarcoma cells. Mitogenic activity selective for osteoblastlike cells was identified in postpubertal but not prepubertal normal prostate. The results demonstrate the existence of osteoblastic growth factors in prostatic tissue whose presence may accompany postpubertal development.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2443538      PMCID: PMC442330          DOI: 10.1172/JCI113186

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  18 in total

1.  A highly sensitive adenylate cyclase assay.

Authors:  Y Salomon; C Londos; M Rodbell
Journal:  Anal Biochem       Date:  1974-04       Impact factor: 3.365

2.  Hypercalcemia and neoplasia: a model system.

Authors:  B F Rice; R L Ponthier; M C Miller
Journal:  Endocrinology       Date:  1971-05       Impact factor: 4.736

Review 3.  Polypeptide growth factors.

Authors:  R James; R A Bradshaw
Journal:  Annu Rev Biochem       Date:  1984       Impact factor: 23.643

4.  Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups.

Authors:  A F Stewart; R Horst; L J Deftos; E C Cadman; R Lang; A E Broadus
Journal:  N Engl J Med       Date:  1980-12-11       Impact factor: 91.245

5.  Identification of a messenger ribonucleic acid fraction in human prostatic cancer cells coding for a novel osteoblast-stimulating factor.

Authors:  E Simpson; J Harrod; G Eilon; J W Jacobs; G R Mundy
Journal:  Endocrinology       Date:  1985-10       Impact factor: 4.736

6.  Mitogenic factor in human prostate extracts.

Authors:  S C Jacobs; R K Lawson
Journal:  Urology       Date:  1980-11       Impact factor: 2.649

7.  Parathyroid hormone-responsive clonal cell lines from rat osteosarcoma.

Authors:  R J Majeska; S B Rodan; G A Rodan
Journal:  Endocrinology       Date:  1980-11       Impact factor: 4.736

8.  Isolation and analysis of human parathyrin in parathyroid tissue and plasma. Use of reversed-phase liquid chromatography.

Authors:  H P Bennett; S Solomon; D Goltzman
Journal:  Biochem J       Date:  1981-08-01       Impact factor: 3.857

9.  Prostatic osteoblastic factor.

Authors:  S C Jacobs; D Pikna; R K Lawson
Journal:  Invest Urol       Date:  1979-11

10.  Epidermal growth factor receptors in clonal lines of a rat osteogenic sarcoma and in osteoblast-rich rat bone cells.

Authors:  K W Ng; N C Partridge; M Niall; T J Martin
Journal:  Calcif Tissue Int       Date:  1983-05       Impact factor: 4.333

View more
  20 in total

1.  Effects of basic fibroblast growth factor on bone formation in vitro.

Authors:  E Canalis; M Centrella; T McCarthy
Journal:  J Clin Invest       Date:  1988-05       Impact factor: 14.808

2.  Oncogenic Role of the Ec Peptide of the IGF-1Ec Isoform in Prostate Cancer.

Authors:  Athanasios Armakolas; Maria Kaparelou; Andreas Dimakakos; Efstathia Papageorgiou; Nikolaos Armakolas; Athanasios Antonopoulos; Constantina Petraki; Maria Lekarakou; Pavlos Lelovas; Martha Stathaki; Constantinos Psarros; Ismene Donta; Panos S Galanos; Paul Msaouel; Vassilis G Gorgoulis; Michael Koutsilieris
Journal:  Mol Med       Date:  2015-01-06       Impact factor: 6.354

3.  Evidence for an osteoblast-activating factor in a patient with peripheral T-cell lymphoma and osteosclerosis.

Authors:  M Hüfner; H Döhner; J Schmidt; P Möller; A D Ho; W Hunstein
Journal:  Klin Wochenschr       Date:  1989-04-03

4.  Glucocorticoid receptor function possibly modulates cell-cell interactions in osteoblastic metastases on rat skeleton.

Authors:  C Reyes-Moreno; M Koutsilieris
Journal:  Clin Exp Metastasis       Date:  1997-05       Impact factor: 5.150

5.  IGF-1 expression in infarcted myocardium and MGF E peptide actions in rat cardiomyocytes in vitro.

Authors:  Anastasia Stavropoulou; Antonios Halapas; Antigone Sourla; Anastassios Philippou; Efstathia Papageorgiou; Apostolos Papalois; Michael Koutsilieris
Journal:  Mol Med       Date:  2009-03-06       Impact factor: 6.354

Review 6.  Hypercalcaemia of malignancy.

Authors:  P J Kelly; J A Eisman
Journal:  Cancer Metastasis Rev       Date:  1989-06       Impact factor: 9.264

7.  Characterization of osteolytic, osteoblastic, and mixed lesions in a prostate cancer mouse model using 18F-FDG and 18F-fluoride PET/CT.

Authors:  Wellington K Hsu; Mandeep S Virk; Brian T Feeley; David B Stout; Arion F Chatziioannou; Jay R Lieberman
Journal:  J Nucl Med       Date:  2008-02-20       Impact factor: 10.057

Review 8.  Prostate cancer progression. Implications of histopathology.

Authors:  J L Ware
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

9.  Rosiglitazone attenuates insulin-like growth factor 1 receptor survival signaling in PC-3 cells.

Authors:  Efstathia Papageorgiou; Nea Pitulis; Menelaos Manoussakis; Peter Lembessis; Michael Koutsilieris
Journal:  Mol Med       Date:  2008 Jul-Aug       Impact factor: 6.354

10.  Expression of PGK1 by prostate cancer cells induces bone formation.

Authors:  Younghun Jung; Yusuke Shiozawa; Jianhua Wang; Jingcheng Wang; Zhuo Wang; Elisabeth A Pedersen; Clara H Lee; Christopher L Hall; Phillip J Hogg; Paul H Krebsbach; Evan T Keller; Russell S Taichman
Journal:  Mol Cancer Res       Date:  2009-10-13       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.